Thyroid Cancer

Genzyme Launches Thyrogen in Europe

Published in Cancer Weekly, November 13th, 2001

Genzyme General, a division of Genzyme Corp., has begun marketing Thyrogen (thyrotropin alfa for injection) in Europe. Thyrogen is a recombinant human thyroid stimulating hormone indicated for use in the management of patients being followed up for the recurrence of well-differentiated thyroid cancer.

In September (2001) the Committee for Proprietary Medicinal Products of the European Medicines Evaluation Agency adopted a positive opinion on a variation to the manufacturing process for Thyrogen, which was necessary for commercial introduction of the product. Thyrogen was approved for marketing in Europe last year and has been available on a named-patient basis since...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry